Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

Abstract

Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells persisting after curative intent therapy1. The study of large patient cohorts incorporating longitudinal plasma sampling and extended follow-up is required to determine the role of ctDNA as a phylogenetic biomarker of relapse in early-stage non-small-cell lung cancer (NSCLC). Here we developed ctDNA methods tracking a median of 200 mutations identified in resected NSCLC tissue across 1,069 plasma samples collected from 197 patients enrolled in the TRACERx study2. A lack of preoperative ctDNA detection distinguished biologically indolent lung adenocarcinoma with good clinical outcome. Postoperative plasma analyses were interpreted within the context of standard-of-care radiological surveillance and administration of cytotoxic adjuvant therapy. Landmark analyses of plasma samples collected within 120 days after surgery revealed ctDNA detection in 25% of patients, including 49% of all patients who experienced clinical relapse; 3 to 6 monthly ctDNA surveillance identified impending disease relapse in an additional 20% of landmark-negative patients. We developed a bioinformatic tool (ECLIPSE) for non-invasive tracking of subclonal architecture at low ctDNA levels. ECLIPSE identified patients with polyclonal metastatic dissemination, which was associated with a poor clinical outcome. By measuring subclone cancer cell fractions in preoperative plasma, we found that subclones seeding future metastases were significantly more expanded compared with non-metastatic subclones. Our findings will support (neo)adjuvant trial advances and provide insights into the process of metastatic dissemination using low-ctDNA-level liquid biopsy. Measurements of subclonal expansion of ctDNA in the plasma before surgery may enable the prediction of future metastatic subclones, offering the possibility for early intervention in patients with non-small-cell lung cancer.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 76

1. 1.

   Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Cancer Discov. 2021;11:2968-2986.

   Not in our library10.1158/2159-8290.cd-21-0634

2. 2.

   Jamal-Hanjani M, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376:2109-2121.

   Not in our library10.1056/nejmoa1616288

3. 3.

   Chabon JJ, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020;580:245-251.

   Not in our library10.1038/s41586-020-2140-0

4. 4.
   Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer · 2020

   Not checked
5. 5.

   Xia L, et al. Perioperative ctDNA-based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1). Clin Cancer Res. 2021.

   Not in our library10.1158/1078-0432.ccr-21-3044

6. 6.

   Chaudhuri AA, et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017;7:1394-1403.

   Not in our library10.1158/2159-8290.cd-17-0716

7. 7.

   Abbosh C, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446-451.

   Not in our library10.1038/nature22364

8. 8.

   Gale D, et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Annals of Oncology. 2022;33.

   Not in our library10.1016/j.annonc.2022.02.007

9. 9.

   Powles T, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595:432-437.

   Not in our library10.1038/s41586-021-03642-9

10. 10.

    Tie J, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022;386:2261-2272.

    Not in our library10.1056/nejmoa2200075

11. 11.

    Parikh AR, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019;25:1415-1421.

    Not in our library10.1038/s41591-019-0561-9

12. 12.
    Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer · 2015

    No notice
13. 13.

    Herberts C, et al. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022.

    Not in our library10.1038/s41586-022-04975-9

14. 14.

    Lung cancer: diagnosis and management NICE guideline [NG122].

    Not in our library

15. 15.

    Zheng Z, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20:1479-1484.

    Not in our library10.1038/nm.3729

16. 16.

    Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018;15:577-586.

    Not in our library10.1038/s41571-018-0058-3

17. 17.

    Newman AM, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548-554.

    Not in our library10.1038/nm.3519

18. 18.
    GSVA: gene set variation analysis for microarray and RNA-Seq data · 2013

    No notice
19. 19.

    Liberzon A, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417-425.

    Not in our library10.1016/j.cels.2015.12.004

20. 20.

    Biswas D, et al. A clonal expression biomarker associates with lung cancer mortality. Nat Med. 2019;25:1540-1548.

    Not in our library10.1038/s41591-019-0595-z

21. 21.

    Burrell RA, et al. Replication stress links structural and numerical cancer chromosomal instability. Nature. 2013;494:492-496.

    Not in our library10.1038/nature11935

22. 22.

    Wang ZC, et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res. 2012;18:5806-5815.

    Not in our library10.1158/1078-0432.ccr-12-0857

23. 23.
    GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers · 2011

    No notice
24. 24.

    Shih DJH, et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020;52:371-377.

    Not in our library10.1038/s41588-020-0592-7

25. 25.
    COSMIC: the Catalogue Of Somatic Mutations In Cancer · 2018

    No notice
26. 26.

    Garcia-Murillas I, et al. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019;5:1473-1478.

    Not in our library10.1001/jamaoncol.2019.1838

27. 27.

    TRACERx 421 primary paper. 2022.

    Not in our library

28. 28.
    Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition · 2021

    No notice
29. 29.

    McGranahan N, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-1469.

    Not in our library10.1126/science.aaf1490

30. 30.
    The evolution of non-small cell lung cancer metastases in TRACERx · 2023

    No notice
31. 31.
    Genomic–transcriptomic evolution in lung cancer and metastasis · 2023

    No notice
32. 32.

    Moding EJ, et al. Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nat Cancer. 2020;1:176-183.

    Not in our library10.1038/s43018-019-0011-0

33. 33.

    Chen K, et al. Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC). Clin Cancer Res. 2019;25:7058-7067.

    Not in our library10.1158/1078-0432.ccr-19-1213

34. 34.

    Li N, et al. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer. Cancer. 2021.

    Not in our library10.1002/cncr.33985

35. 35.

    Kurtz DM, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39:1537-1547.

    Not in our library10.1038/s41587-021-00981-w

36. 36.

    Cohen JD, et al. Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. Nat Biotechnol. 2021;39:1220-1227.

    Not in our library10.1038/s41587-021-00900-z

37. 37.

    Gydush G, et al. Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. Nat Biomed Eng. 2022;6:257-266.

    Not in our library10.1038/s41551-022-00855-9

38. 38.

    Van Loo P, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A. 2010;107:16910-16915.

    Not in our library10.1073/pnas.1009843107

39. 39.
    The Life History of 21 Breast Cancers · 2012

    Corrected
40. 40.

    Roth A, et al. PyClone: statistical inference of clonal population structure in cancer. Nat Methods. 2014;11:396-398.

    Not in our library10.1038/nmeth.2883

Cited by papers we hold 5

• Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation · 2024
  No notice
• The two sides of chromosomal instability: drivers and brakes in cancer · 2024
  No notice
• Cancer biomarkers: Emerging trends and clinical implications for personalized treatment · 2024
  No notice
• The evolution of non-small cell lung cancer metastases in TRACERx · 2023
  No notice
• Genomic–transcriptomic evolution in lung cancer and metastasis · 2023
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.